Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination
Year: 2025
Type: article
Study design: Observational Study
Abstract: We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 cancer patients, to discover clinical and molecular determinants that predispose cancer patients to breakthrough infections. Patients with B cell malignancies, with differential expression of CD24, CDK14 and PLEKHG1, were most susceptible to breakthrough infections, suggesting that these patients may require more booster immunisations to ameliorate cellular responses and immune protection against COVID-19.
Source: npj Vaccines
Authors: Youjia Zhong, Jiaqi Li, Ainsley Ryan Yan Bin Lee, Janice Yu Jin Tan, Carina Jing Xuan Tay, Clara WT Koh, Ethan Yong Tzi Seow, Wee Chee Yap, Shi Yin Wong, Chun En Yau, Chen Ee Low, Kelvin Bryan Tan, Barnaby Edward Young, Yan Su, Arun George Devasia, Perumal Dharuman, Alexander Lezhava, Rahul Pandey, Panneer Selvi Govindaraju, Sidney Yee, Ruifen Weng, Candy Khoo, Shaun Shi Yan Tan, Matilda Lee, Joline Lim, Esther Chan, Carol LF Ho, Louis Yi Ann Chai, Chee Wah Tan, Soo Chin Lee, Kuan Rong Chan, Raghav Sundar
Institutions: National University of Singapore, Duke-NUS Medical School, National University Health System, Stanford Medicine, Stanford University, Ministry of Health, Nanyang Technological University, Tan Tock Seng Hospital, National Centre for Infectious Diseases, Agency for Science, Technology and Research, Genome Institute of Singapore, Diagnostics Development Hub, National University Hospital, National University Cancer Institute, Singapore
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,890
Awards: G2502743332, G7278023611, G819443284
OpenAlex ID: W4410194363